Octave Bioscience Reels in $35.6 Million Series C

<p><strong>MENLO PARK<&sol;strong> &&num;8212&semi; Octave Bioscience&comma; Inc&period;&comma; a commercial stage precision care company that is pioneering a new standard for managing multiple sclerosis &lpar;MS&rpar; and other neurodegenerative diseases&comma; announces the close of its &dollar;35&period;6 million Series C equity financing and that it has entered into a &dollar;15&period;5 million non-dilutive term loan agreement with Silicon Valley Bank &lpar;SVB&rpar; a Division of First Citizens Bank&period;<&sol;p>&NewLine;<p>The financing comes amidst strong commercial momentum for its flagship product&comma; the Octave MSDA test&comma; with the company achieving broad physician adoption and payer reimbursement with over 325 prescribers&comma; more than 19&comma;000 patient tests delivered to date&comma; and in-network reimbursement with over 75 million contracted lives at favorable rates&period; Proceeds of the financing will support continued commercialization of Octave’s MSDA test&comma; a first-of-its-kind test for MS disease activity&comma; as well as advancement of the company’s pipeline in Parkinson’s disease&period;<&sol;p>&NewLine;<p>The equity round included participation from new strategic investors as well as participation by existing investors including Byers Capital&comma; Blue Venture Fund&comma; Northpond Ventures&comma; S32&comma; Casdin Capital&comma; Merck Global Health Innovation Fund&comma; Novartis&comma; Valhalla Foundation&comma; Intermountain Ventures and Hikma Ventures&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;Octave Bioscience’s precision medicine testing platform is driving personalized insights for neurodegenerative diseases and changing how they are managed&period; The company’s multi-analyte blood-based tests provide quantitative and clinically actionable insights&comma; enabling physicians to make more confident&comma; impactful treatment decisions that can lead to improved patient outcomes&comma;” said Brook Byers&comma; Byers Capital&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;This Series C funding empowers us to establish the Octave MSDA Test as the new standard of care in multiple sclerosis&comma;&OpenCurlyDoubleQuote; said Doug Biehn&comma; Chief Executive Officer of Octave&period; &OpenCurlyDoubleQuote;Beyond MS&comma; these resources significantly advance Octave’s mission to become the leading precision neurology platform in the world&comma; ultimately impacting the lives of individuals with neurodegenerative diseases like Parkinson&&num;8217&semi;s and Alzheimer&&num;8217&semi;s&period;”<&sol;p>&NewLine;

Editor

Intel Names New Foundry Leader

SANTA CLARA — Intel Corporation has appointed Seok-Hee Lee [photo above] as executive vice president…

2 days

Parafin Launches Spend Business Credit Card

SAN FRANCISCO -- Parafin, a financial infrastructure company that provides platforms with embedded financial products…

2 days

Hang Ten Reels In $32 Million

PALO ALTO -- Hang Ten Systems, an enterprise AI services company, has raised $32 million…

2 days

Doordash Offers Auto Parts Delivery

DoorDash is racing into the auto parts category. Millions of customers nationwide can now shop…

2 days

Microsoft Breaks Ground on Data Center in Alviso

SAN JOSE – HITT Contracting announced the groundbreaking of Microsoft’s new Alviso datacenter campus in San…

3 days

Convey Lands $38 Million Series A

SAN FRANCISCO — Convey, an enterprise AI platform that enables non-technical operators to build and manage…

3 days